Surface Plasmon Resonance Biosensor for Real-time Measurements from Living Cells


Florida International University (FIU) is seeking a business partner to develop and commercialize a Surface Plasmon Resonance (SPR) Biosensor that can be used for direct measurements of secretions from living cells. Previously established SPR based sensing platforms have been limited to detection of analytes in a prepared sample. This requires collection of analytes from the cell culture media, purification, and pretreatment of analytes for the purpose of cellular exocytosis and cellular signaling pathway studies. These redundant steps are time consuming, and also introduce unpredictable errors to the experiments.

Among all types of cellular secretions, biomarkers are most significant for clinical, medical and biochemical applications. Protein biomarkers are widely involved in the development of many types of cancer. Vascular endothelial growth factor (VEGF) is a widely studied angiogenic signal protein biomarker. Real-time, direct measurements of VEGF from carcinoma cells are required to understand its metabolism and for drug development. The FIU invention is a new concept of an in situ SPR biosensing system for realtime VEGF secretion study. A mini cell culture module has been integrated to the SPR system. Unlike the traditional configuration of SPR systems for biomarker detection, living cells are cultured in a customized SPR flow cell chamber, and biomarker secretion from the cells is rapidly monitored by an immune SPR sensing device. As a model system, SKOV-3 ovarian cancer cell line was used to demonstrate VEGF secretion live time measurement. Since the novel biosensor mimics the in vivo microenvironment of the biomarker signaling pathway, this platform possesses great potential for cellular signaling pathway studies and for antineoplastic drug development.


This biosensor is capable of direct measurement of biomarker secretion from living cells. This platform can be used for cellular signaling pathway studies and for antineoplastic drug development. By modifying the surface functionality of the SPR assay, this biosensor might open up new horizons for the detection and analysis of biomarker from living cells and tissue for different diseases.

  • Direct measurement of protein biomarkers
  • Inexpensive, accurate, and faster than existing technologies
  • No pretreatment to cells.

For additional information about this technology opportunity, please contact Shantanu Balkundi at or by phone at 305-348-8061 and ask about record IP 1228.